Kiniksa Pharmaceuticals International Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Kiniksa Pharmaceuticals International has been growing earnings at an average annual rate of 45.9%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been growing at an average rate of 65.2% per year.
Belangrijke informatie
45.9%
Groei van de winst
48.9%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 17.0% |
| Inkomstengroei | 65.2% |
| Rendement op eigen vermogen | -2.1% |
| Nettomarge | -2.4% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Kiniksa Pharmaceuticals: Looking In On A Developing Growth Story
Oct 07Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 07
Kiniksa Pharmaceuticals: Improved Outlook For Arcalyst After Q2 Beat
Jul 24Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Share Price Is Matching Sentiment Around Its Revenues
Jun 19Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17Opbrengsten en kosten
Hoe Kiniksa Pharmaceuticals International geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 384 | -9 | 164 | 96 |
| 30 Jun 24 | 339 | -10 | 152 | 88 |
| 31 Mar 24 | 302 | 9 | 139 | 87 |
| 31 Dec 23 | 270 | 14 | 129 | 76 |
| 30 Sep 23 | 249 | -7 | 120 | 70 |
| 30 Jun 23 | 281 | 231 | 110 | 70 |
| 31 Mar 23 | 236 | 196 | 105 | 60 |
| 31 Dec 22 | 220 | 183 | 98 | 65 |
| 30 Sep 22 | 177 | 143 | 93 | 79 |
| 30 Jun 22 | 90 | -112 | 90 | 81 |
| 31 Mar 22 | 71 | -134 | 88 | 91 |
| 31 Dec 21 | 39 | -158 | 86 | 99 |
| 30 Sep 21 | 20 | -175 | 79 | 109 |
| 30 Jun 21 | 8 | -189 | 70 | 121 |
| 31 Mar 21 | 0 | -184 | 57 | 120 |
| 31 Dec 20 | 0 | -161 | 45 | 112 |
| 30 Sep 20 | 0 | -140 | 38 | 99 |
| 30 Jun 20 | 0 | -123 | 35 | 89 |
| 31 Mar 20 | 0 | -122 | 35 | 97 |
| 31 Dec 19 | 0 | -162 | 35 | 135 |
| 30 Sep 19 | 0 | -173 | 35 | 147 |
| 30 Jun 19 | 0 | -170 | 31 | 146 |
| 31 Mar 19 | 0 | -153 | 27 | 133 |
| 31 Dec 18 | 0 | -103 | 22 | 87 |
| 30 Sep 18 | 0 | -93 | 16 | 80 |
| 30 Jun 18 | 0 | -85 | 13 | 74 |
| 31 Mar 18 | 0 | -76 | 11 | 65 |
| 31 Dec 17 | 0 | -65 | 9 | 56 |
Kwaliteitswinsten: KNSA is currently unprofitable.
Groeiende winstmarge: KNSA is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: KNSA is unprofitable, but has reduced losses over the past 5 years at a rate of 45.9% per year.
Versnelling van de groei: Unable to compare KNSA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: KNSA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: KNSA has a negative Return on Equity (-2.08%), as it is currently unprofitable.